Skip to main content

Table 4 Effect sizes: PNH patients after 26 weeks of treatment compared to general population

From: Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria

  1. Conditional formatting shows the magnitude and direction (green = better health status; red = worse health status) of the adjusted mean differences. General Population N = 15,386.
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172